A Study of BBI503 in Adult Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

311

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Cancer, Advanced Solid Tumors
Interventions
DRUG

BBI503

Trial Locations (19)

22031

Virginia Cancer Specialists, P.C., Fairfax

23502

Virginia Oncology Associates, Norfolk

29605

Institute for Translational Oncology Research, Greenville Hospital System, Greenville

46202

Indiana University, Indianapolis

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

55905

Mayo Clinic Cancer Center, Rochester, Rochester

75246

Texas Oncology- Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology- Tyler, Tyler

76104

Texas Oncology- Fort Worth, Fort Worth

78217

Cancer Care Centers of South Texas, San Antonio

78229

Cancer Care Centers of South Texas - HOAST, San Antonio

80218

Rocky Mountain Cancer Centers, Denver

85259

Mayo Clinic Cancer Center, Scottsdale, Scottsdale

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

98902

Yakima Memorial Hostpial/North Star Lodge, Yakima

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

K1H 8L6

Ottawa Hospital Cancer Centre, Ottawa

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT01781455 - A Study of BBI503 in Adult Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter